Discovered by Jennifer Doudna at UC Berkeley in 2012, CRISPR/Cas9, a precise tool for genome editing, is now being used in laboratories all over the world to enhance our understanding of how living biological systems work, how to improve treatments for genetic diseases, and how to develop energy solutions for a better future. Recently, a team led by Innovative Genomics Initiative (IGI) Affiliate Alex Marson (UCSF) and IGI Executive Director Jennifer Doudna (UC Berkeley, Berkeley Lab, HHMI) devised a new strategy to precisely modify human immune-system “T cells” using CRISPR/Cas9 technology. More on this research can be found here.
Dr. Jennifer Doudna is the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences, and a member of the departments of Molecular and Cell Biology and Chemistry at the University of California, Berkeley. She is also a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, the National Academy of Sciences, and the American Academy of Arts and Sciences. The Doudna Lab at UC Berkeley pursues mechanistic understanding of fundamental biological processes involving RNA molecules, currently focused on three major areas – bacterial immunity via the CRISPR system, RNA interference in eukaryotes, and translational control logic – and utilizing diverse techniques including X-ray crystallography, high-throughput sequencing, biochemistry, molecular biology, and eukaryotic cell culture. Dr. Doudna serves as the Executive Director of the Li Ka Shing Center for Genomic Engineering.